Corcept Therapeutics shares surge on positive late-stage ovarian cancer trial results
Corcept Therapeutics (NASDAQ:CORT) shares surged more than 85% after the company announced positive results from its Phase 3 ROSELLA trial, evaluating relacorilant combined with nab-paclitaxel in patients with platinum-resistant ovarian cancer, that will support regulatory applications in the US and Europe. The trial met its primary endpoint, demonstrating a 30% reduction in the risk of disease progression compared to nab-paclitaxel alone.
Corcept's ovarian cancer combination drug meets main goal in late-stage study
Corcept Therapeutics said on Monday its experimental ovarian cancer drug in combination with chemotherapy met the main goal of a late-stage trial.
Why Is Corcept (CORT) Down 5.3% Since Last Earnings Report?
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
Is Corcept Therapeutics (CORT) Stock Outpacing Its Medical Peers This Year?
Here is how Corcept Therapeutics (CORT) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Corcept Shares Rise More Than 55% in 6 Months: Here's Why
CORT's Cushing's syndrome drug, Korlym, is driving revenues. The FDA's acceptance of the NDA for relacorilant also bodes well.
Privia Health, Corcept and three other low-key but high-earnings growth potential stocks to invest in 2025
With the broader market facing volatility, a clutch of experts are recommending investors to look beyond mega-cap stocks like Meta, Amazon, and Netflix for opportunities in stocks with strong earnings growth potential.
3 Reasons Why Growth Investors Shouldn't Overlook Corcept (CORT)
Corcept (CORT) possesses solid growth attributes, which could help it handily outperform the market.
Why Corcept Therapeutics (CORT) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is Corcept Therapeutics (CORT) Outperforming Other Medical Stocks This Year?
Here is how Corcept Therapeutics (CORT) and Delcath Systems, Inc. (DCTH) have performed compared to their sector so far this year.
CORT's Q4 Earnings and Revenues Fall Short of Estimates
Corcept reports weaker-than-expected results for the fourth quarter of 2024. Korlym drives year-over-year sales.
Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Corcept Therapeutics, Inc. (CORT) Q4 2024 Earnings Call Transcript
Corcept Therapeutics, Inc. (NASDAQ:CORT ) Q4 2024 Earnings Conference Call February 26, 2025 5:00 PM ET Company Participants Atabak Mokari - CFO & Treasurer Gary Robb - Chief Business Officer & Secretary Joe Belanoff - Co-Founder, President, CEO & Director Bill Guyer - Chief Development Officer Sean Maduck - President, Endocrinology Conference Call Participants David Amsellem - Piper Sandler Swayampakula Ramakanth - H.C. Wainwright Asim Rana - Truist Operator Thank you for standing by, and welcome to Corcept Therapeutics conference call.
